SE9602280D0 - Immunstimulerande lipidformulering - Google Patents

Immunstimulerande lipidformulering

Info

Publication number
SE9602280D0
SE9602280D0 SE9602280A SE9602280A SE9602280D0 SE 9602280 D0 SE9602280 D0 SE 9602280D0 SE 9602280 A SE9602280 A SE 9602280A SE 9602280 A SE9602280 A SE 9602280A SE 9602280 D0 SE9602280 D0 SE 9602280D0
Authority
SE
Sweden
Prior art keywords
immune
lipid formulation
stimulating lipid
carbon atoms
stimulating
Prior art date
Application number
SE9602280A
Other languages
English (en)
Swedish (sv)
Inventor
Ulf Schroeder
Original Assignee
Pharmatrix Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatrix Ab filed Critical Pharmatrix Ab
Priority to SE9602280A priority Critical patent/SE9602280D0/xx
Publication of SE9602280D0 publication Critical patent/SE9602280D0/xx
Priority to JP50151498A priority patent/JP4147328B2/ja
Priority to AU31998/97A priority patent/AU724655B2/en
Priority to ES97927561T priority patent/ES2227698T3/es
Priority to NZ333226A priority patent/NZ333226A/xx
Priority to DE69730434T priority patent/DE69730434T2/de
Priority to CA2258017A priority patent/CA2258017C/en
Priority to PCT/SE1997/001003 priority patent/WO1997047320A1/en
Priority to US09/147,367 priority patent/US7128909B2/en
Priority to EP97927561A priority patent/EP0918541B9/en
Priority to US11/524,192 priority patent/US20070020282A1/en
Priority to US12/076,981 priority patent/US20080187553A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SE9602280A 1996-06-10 1996-06-10 Immunstimulerande lipidformulering SE9602280D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE9602280A SE9602280D0 (sv) 1996-06-10 1996-06-10 Immunstimulerande lipidformulering
EP97927561A EP0918541B9 (en) 1996-06-10 1997-06-09 Immunstimulating lipid formulation
NZ333226A NZ333226A (en) 1996-06-10 1997-06-09 Immunstimulating lipid formulation
AU31998/97A AU724655B2 (en) 1996-06-10 1997-06-09 Immunstimulating lipid formulation
ES97927561T ES2227698T3 (es) 1996-06-10 1997-06-09 Formulacion de lipidos inmunoestimuladores.
JP50151498A JP4147328B2 (ja) 1996-06-10 1997-06-09 免疫刺激するリピド製剤
DE69730434T DE69730434T2 (de) 1996-06-10 1997-06-09 Immunstimulierende lipidformulierung
CA2258017A CA2258017C (en) 1996-06-10 1997-06-09 Immunstimulating lipid formulation
PCT/SE1997/001003 WO1997047320A1 (en) 1996-06-10 1997-06-09 Immunstimulating lipid formulation
US09/147,367 US7128909B2 (en) 1996-06-10 1997-06-09 Immunstimulating lipid formulation
US11/524,192 US20070020282A1 (en) 1996-06-10 2006-09-21 Immunstimulating lipid formulation
US12/076,981 US20080187553A1 (en) 1996-06-10 2008-03-26 Immunstimulating lipid formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9602280A SE9602280D0 (sv) 1996-06-10 1996-06-10 Immunstimulerande lipidformulering

Publications (1)

Publication Number Publication Date
SE9602280D0 true SE9602280D0 (sv) 1996-06-10

Family

ID=20402941

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9602280A SE9602280D0 (sv) 1996-06-10 1996-06-10 Immunstimulerande lipidformulering

Country Status (10)

Country Link
US (3) US7128909B2 (xx)
EP (1) EP0918541B9 (xx)
JP (1) JP4147328B2 (xx)
AU (1) AU724655B2 (xx)
CA (1) CA2258017C (xx)
DE (1) DE69730434T2 (xx)
ES (1) ES2227698T3 (xx)
NZ (1) NZ333226A (xx)
SE (1) SE9602280D0 (xx)
WO (1) WO1997047320A1 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001500738A (ja) 1996-09-17 2001-01-23 カイロン コーポレイション 細胞内疾患を処置するための組成物および方法
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
SE0100011D0 (sv) * 2001-01-03 2001-01-03 Eurocine Ab Karolinska Inst Sc Virus vaccine formulation
US20030072764A1 (en) * 2001-04-05 2003-04-17 O'hagan Derek Mucosal boosting following parenteral priming
JP2005509598A (ja) * 2001-08-16 2005-04-14 リュフヤトルン・エイチエフ，バイオファーマシューティカルズ エクスビボで抗体を産生する方法
AU2003215884A1 (en) * 2002-02-25 2003-09-09 Lyfjathroun Hf A bioadhesive agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
ATE480258T1 (de) * 2002-11-26 2010-09-15 Eurocine Vaccines Ab Neue adjuvant auf der basis von aminen
ES2375267T3 (es) 2005-01-28 2012-02-28 North-West University Combinación de lípidos y de óxido nitroso como adyuvante para potenciar de la eficacia de vacunas.
WO2008121926A1 (en) 2007-03-30 2008-10-09 Particle Sciences, Inc. Particle formulations and uses thereof
AU2010275475B2 (en) * 2009-07-24 2013-10-03 Spinal Usa, Inc. Bone plate screw-blocking systems and methods
BR112013007355A2 (pt) * 2010-09-30 2016-07-12 Eurocine Vaccines Ab composições de vacina aprimoradas
RU2483748C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря
RU2483749C2 (ru) * 2011-04-15 2013-06-10 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки
EP2742952A1 (en) 2012-12-17 2014-06-18 Eurocine Vaccines AB Influenza vaccine composition
TW202200012A (zh) 2020-03-11 2022-01-01 美商富曼西公司 殺真菌劑混合物
TW202342431A (zh) 2022-02-15 2023-11-01 美商富曼西公司 殺真菌的鹵代甲基酮、水合物和烯醇醚

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531565A (en) * 1969-09-25 1970-09-29 American Cyanamid Co Stable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acid
GB1374325A (en) * 1972-10-05 1974-11-20 Merck & Co Inc Isomannide monooleate
US4073743A (en) * 1975-04-17 1978-02-14 Merck & Co., Inc. Process for preparing an emulsion
US4446165A (en) * 1979-06-08 1984-05-01 The Procter & Gamble Company Oleaginous compositions
US5837249A (en) * 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
US5055446A (en) * 1988-10-21 1991-10-08 University Of Cincinnati Method to improve survival of patients during sepsis by diet composition
AU626049B2 (en) * 1989-05-29 1992-07-23 Lion Corporation Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop
US5256641A (en) * 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
CA2114125A1 (en) * 1991-07-26 1993-02-18 Wayne G. Reilly Self-adjuvanting peptide vaccine delivery system and production thereof
WO1993006921A1 (en) * 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
CA2083553A1 (en) 1991-11-25 1993-05-26 Kuniharu Seki Immunogen composition
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
BR9506885A (pt) 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
JP3770628B2 (ja) * 1994-08-09 2006-04-26 サントリー株式会社 遅延型アレルギー反応を介する医学的症状の予防及び改善剤
US5730989A (en) * 1995-02-16 1998-03-24 Novavax, Inc. Oral vaccine against gram negative bacterial infection

Also Published As

Publication number Publication date
CA2258017C (en) 2011-05-24
AU3199897A (en) 1998-01-07
US20020012673A1 (en) 2002-01-31
JP2000512292A (ja) 2000-09-19
JP4147328B2 (ja) 2008-09-10
US20080187553A1 (en) 2008-08-07
EP0918541B1 (en) 2004-08-25
AU724655B2 (en) 2000-09-28
DE69730434D1 (de) 2004-09-30
EP0918541A1 (en) 1999-06-02
DE69730434T2 (de) 2005-09-15
WO1997047320A1 (en) 1997-12-18
CA2258017A1 (en) 1997-12-18
EP0918541B9 (en) 2008-06-18
ES2227698T3 (es) 2005-04-01
US20070020282A1 (en) 2007-01-25
NZ333226A (en) 2000-05-26
US7128909B2 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
SE9602280D0 (sv) Immunstimulerande lipidformulering
ITBO980596A0 (it) Preparazione per la veicolazione di principi attivi basata su acidi gr assi polinsaturi del gruppo omega 3 .
CA2259297A1 (en) Parenteral paclitaxel in a stable non-toxic formulation
NL193340B (nl) Farmaceutisch preparaat voor parenterale toediening gevormd uit een vetemulsie.
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
DE69114498T2 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
NO993096L (no) Orale cyklosporinformuleringer
DK1233969T3 (da) Mono- og disaccharridderivater
IE871203L (en) Formulations containing unsaturated fatty acids
ES8708183A1 (es) Un procedimiento para la preparacion de una composicion liofilizada de lipidos.
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
IT1229562B (it) Composizioni farmaceutiche antivirali ed immunostimolanti e procedimento per la loro preparazione.
ATE308983T1 (de) Verwendung natürlicher physiologisch aktiver substanzen gegen parasitäre fischerkrankungen
WO2000047225A3 (en) Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
FR2705097B1 (fr) Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent.
WO1999039682A3 (en) Lipid mixtures and their use
GB2311533B (en) Esters of polyunsaturated fatty acids
AU1227700A (en) Method for the production of purified invasin protein and use thereof
DE68908414D1 (de) Pharmazeutische zusammensetzungen fuer die reizung eines immunostimulierenden effektes.
CA2293367A1 (en) Wax esters enriched in .omega.-3 unsaturated fatty acids, their preparation and their use
IT9003728A0 (it) Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazionee formulazioni farmaceutiche che li contengono.
GR3019776T3 (en) Antineoplastic medicament containing octadecyl-[2-(N-methylpiperidino)-ethyl] phosphate and synthesis thereof
NL185454C (nl) Esterderivaat van een anti-inflammatoir werkzaam carbonzuur, werkwijze voor het bereiden daarvan en farmaceutisch preparaat met anti-inflammatoire werking.
SE0100011D0 (sv) Virus vaccine formulation
IT8719221A0 (it) Composizioni farmaceutiche contenenti levodopa metil estere, loro prodecimento di preparazione e relative applicazioni terapeutiche.